Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Francesca Montanari, MD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Jennifer Kimberly Lue, MD, Enrica Marchi, MD, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 2909.

https://doi.org/10.1182/blood-2019-131841

Published: 2019

Journal Articles

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Helen Ma, MD, Enrica Marchi, MD, PhD, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 3486.

https://doi.org/10.1182/blood-2019-123587

Published: 2019

Journal Articles

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Francesca Montanari, MD, Enrica Marchi, MD, PhD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2018-99-116605

Published: 2018

Journal Articles

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Enrica Marchi, MD, PhD, Emily Lichtenstein, RN, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Celeste Rojas, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2017) 130 (Supplement 1): 1515.

https://doi.org/10.1182/blood.V130.Suppl_1.1515.1515

Published: 2017

Journal Articles

Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate

Owen A. O'Connor, MD PhD, Enrica Marchi, MD PhD, Weining Volinn, PhD, Won Seog Kim, MD PhD

Blood (2016) 128 (22): 4149.

https://doi.org/10.1182/blood.V128.22.4149.4149

Published: 2016

Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD

Blood (2015) 126 (23): 1282.

https://doi.org/10.1182/blood.V126.23.1282.1282

Published: 2015

Journal Articles

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Michael Mangone, PhD, Anna H Mei, BA, Luigi Scotto, PhD, Michele Visentin, PhD, Enrica Marchi, MD, PhD, I. David Goldman, MD, Constantine S. Mitsiades, MD, PhD, Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2013) 122 (21): 4430.

https://doi.org/10.1182/blood.V122.21.4430.4430

Published: 2013

Journal Articles

The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma

Owen A. O'Connor, MD, PhD, Enrica Marchi, MD, PhD, Kelly Zullo, BS, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Fabio Fuligni, Pier Luigi Zinzani, MD, Stefano A. Pileri, Pier Paolo Piccaluga, MD, PhD

Blood (2013) 122 (21): 646.

https://doi.org/10.1182/blood.V122.21.646.646

Published: 2013

Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2725.

https://doi.org/10.1182/blood.V120.21.2725.2725

Published: 2012

Journal Articles

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Salvia Jain, MD, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Matko Kalac, MD, Ph.D., Jennifer Amengual, M.D., Jairo Baquero Buitrago, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 2725.

https://doi.org/10.1182/blood.V118.21.2725.2725

Published: 2011

Journal Articles

Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma

Enrica Marchi, MD, Ph.D., Matko Kalac, MD, Ph.D., Danielle C Bongero, Christine M McIntosh, Laura K Fogli, Luigi Scotto, Ph.D., Maura Rossi, Ph.D., Pier Luigi Zinzani, MD, PhD, Stefano Pileri, MD, Pier Paolo Piccaluga, Sr., MD, PhD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 2727.

https://doi.org/10.1182/blood.V118.21.2727.2727

Published: 2011

Journal Articles

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Catherine S. Diefenbach, MD, Rachel Sabado, PhD, Christopher L. Brooks, PhD, Jairo Baquero-Buitrago, MSc, Crystal Cruz, Isabelita Vengco, Francesca Montanari, MD, Enrica Marchi, MD, Ph.D., Luigi Scotto, Ph.D., Thomas P. Cirrito, PhD, Ivan Bergstein, MD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 3737.

https://doi.org/10.1182/blood.V118.21.3737.3737

Published: 2011

Journal Articles

Therapeutic Targeting of the Bcl-6: p53 Axis with Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma,

Jennifer E Amengual, MD, Matko Kalac, MD, Ph.D., Luigi Scotto, Ph.D., Patrick A Sleckman, Enrica Marchi, MD, Ph.D., Changchun Deng, MD, PhD, Danielle C Bongero, Salvia Jain, MD, Jairo Baquero Buitrago, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 3733.

https://doi.org/10.1182/blood.V118.21.3733.3733

Published: 2011

Journal Articles

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

Michael Mangone, AB, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2011) 118 (21): 1831.

https://doi.org/10.1182/blood.V118.21.1831.1831

Published: 2011

Journal Articles

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

Enrica Marchi, MD, Ph, D, Danielle C Bongero, Matko Kalac, MD, PhD, Luigi Scotto, Ph.D., Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 3937.

https://doi.org/10.1182/blood.V116.21.3937.3937

Published: 2010

Journal Articles

Generation and Characterization of a Novel CD19-CherryLuciferase (CD19CL) Mouse Model: A New Fluorescent/Bioluminescent Model for the Study of B-Cell Development and Lymphomagenesis

Luigi Scotto, Ph.D., Marianna Kruithof de Julio, Ph.D., Luca Paoluzzi, MD, Matko Kalac, MD, Ph.D., Enrica Marchi, MD, Ph.D., Jairo Baquero Buitrago, BS, Owen A. O'Connor, MD, Ph.D.

Blood (2010) 116 (21): 3940.

https://doi.org/10.1182/blood.V116.21.3940.3940

Published: 2010

Journal Articles

Pralatrexate (PDX) Compliments the Activity of the Proteasome Inhibitor Bortezomib (B) in in Vitro Models of Lymphoid T-Cell Malignancies

Enrica Marchi, MD, Luca Paoluzzi, MD, Seshan E Venkatraman, Owen A. O’Connor, MD, PhD

Blood (2008) 112 (11): 3619.

https://doi.org/10.1182/blood.V112.11.3619.3619

Published: 2008

Journal Articles

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Pier Luigi Zinzani, MD, PhD, Vittorio Stefoni, MD, Valentina Ambrosini, MD, Enrico Derenzini, MD, Gerardo Musuraca, MD, Enrica Marchi, MD, Lapo Alinari, MD, Mariapaola Fina, MD, Monica Tani, MD, Cinzia Pellegrini, MD, Stefano Fanti, MD, Michele Baccarani, MD

Blood (2007) 110 (11): 216.

https://doi.org/10.1182/blood.V110.11.216.216

Published: 2007

Journal Articles

Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.

Pier Luigi Zinzani, MD, PhD, Monica Tani, MD, Gerardo Musuraca, MD, Vittorio Stefoni, MD, Enrica Marchi, MD, Mariapaola Fina, MD, Michele Baccarani, MD, PhD

Blood (2006) 108 (11): 2462.

https://doi.org/10.1182/blood.V108.11.2462.2462

Published: 2006

Journal Articles

A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Pier Luigi Zinzani, MD, PhD, Monica Tani, MD, Stefano Fanti, MD, Vittorio Stefoni, MD, Gerardo Musuraca, MD, Paolo Castellucci, MD, Enrica Marchi, MD, Mariapaola Fina, MD, Michele Baccarani, MD,PhD

Blood (2006) 108 (11): 2431.

https://doi.org/10.1182/blood.V108.11.2431.2431

Published: 2006

NARROW

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Therapeutic Targeting of the Bcl-6: p53 Axis with Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma,

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma

Generation and Characterization of a Novel CD19-CherryLuciferase (CD19CL) Mouse Model: A New Fluorescent/Bioluminescent Model for the Study of B-Cell Development and Lymphomagenesis

Pralatrexate (PDX) Compliments the Activity of the Proteasome Inhibitor Bortezomib (B) in in Vitro Models of Lymphoid T-Cell Malignancies

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.

A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only